Serum Institute Partners with Gates MRI to Manufacture Experimental TB Vaccine Candidate
The Serum Institute of India (SII) has partnered with the Gates Medical Research Institute (Gates MRI) to manufacture the M72 AS01E tuberculosis vaccine candidate, currently in late-stage Phase III trials. Pending successful trial results and regulatory approvals, SII plans to invest over $100 million to scale production for countries with high TB burdens. Gates MRI will transfer manufacturing technology, while GSK will supply an adjuvant. This vaccine could be the first new adult TB vaccine in over a century, aiming to complement the existing BCG vaccine and address a major global health challenge.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 31/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- economictimes— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles present a largely neutral and factual perspective focused on public health and scientific collaboration. They highlight the roles of global health organizations and pharmaceutical companies without political framing. The coverage emphasizes the potential health impact and investment plans, reflecting a consensus on the importance of addressing tuberculosis without partisan viewpoints.
The overall tone is cautiously optimistic, emphasizing the potential benefits of the new vaccine and the significant investment by Serum Institute. While acknowledging the vaccine is still under trial and pending approval, the articles convey hope for a major advancement in TB prevention. The sentiment is positive but measured, reflecting the uncertainty inherent in ongoing clinical development.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.